Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

Pharmacoeconomics of subcutaneous allergen immunotherapy.

Incorvaia C, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M, Cadario G, Campi P, Cardinale F, Romano C, Ciprandi G, D'Anneo R, Dal Bo S, Di Gioacchino M, Fiocchi A, Galimberti M, Galli E, Giovannini M, La Grutta S, Lombardi C, Marcucci F, Marseglia GL, Mastrandrea F, Minelli M, Nettis E, Novembre E, Ortolani C, Pajno G, Piras PP, Passalacqua G, Patriarca G, Pucci S, Quercia O, Romano A, Schiavino D, Sforza M, Tosca MA, Tripodi S, Zambito M, Puccinelli P, Frati F.

Eur Ann Allergy Clin Immunol. 2007;39 Spec No:17-20.

PMID:
18924462
2.

Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France.

Omnes LF, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G, Chicoye A, Champion L, Fadel R.

Eur Ann Allergy Clin Immunol. 2007 May;39(5):148-56.

PMID:
17626329
3.

Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy.

Petersen KD, Gyrd-Hansen D, Dahl R.

Allergol Immunopathol (Madr). 2005 Nov-Dec;33(6):296-302.

PMID:
16371215
4.

Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.

Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, Willich SN.

Ann Allergy Asthma Immunol. 2008 Sep;101(3):316-24. doi: 10.1016/S1081-1206(10)60498-X.

PMID:
18814456
5.

Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma.

Ariano R, Berto P, Tracci D, Incorvaia C, Frati F.

Allergy Asthma Proc. 2006 Mar-Apr;27(2):159-63.

PMID:
16724637
6.

Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma.

Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB.

Allergy. 2008 Dec;63(12):1624-9. doi: 10.1111/j.1398-9995.2008.01743.x.

7.

Clinical and patient based evaluation of immunotherapy for grass pollen and mite allergy.

Dam Petersen K, Gyrd-Hansen D, Kjaergaard S, Dahl R.

Allergol Immunopathol (Madr). 2005 Sep-Oct;33(5):264-9.

PMID:
16287545
8.

Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma.

Berto P, Bassi M, Incorvaia C, Frati F, Puccinelli P, Giaquinto C, Cantarutti L, Ortolani C.

Eur Ann Allergy Clin Immunol. 2005 Oct;37(8):303-8.

PMID:
17066648
9.

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB.

Clin Exp Allergy. 2007 May;37(5):772-9.

PMID:
17456225
10.

[Clinical efficacy and costs of the three-year specific allergen immunotherapy--retrospective study].

Targowski T, Jahnz-Rózyk K, Przekora P, Kucharczyk A, Owczarek W.

Pol Merkur Lekarski. 2011 Aug;31(182):106-10. Polish.

PMID:
21936348
11.

Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe.

Canonica GW, Poulsen PB, Vestenbaek U.

Respir Med. 2007 Sep;101(9):1885-94. Epub 2007 Jul 3.

12.

Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study.

Berto P, Passalacqua G, Crimi N, Frati F, Ortolani C, Senna G, Canonica GW; Italian SPAI Study Group.

Ann Allergy Asthma Immunol. 2006 Nov;97(5):615-21.

PMID:
17165269
13.

Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study.

Berto P, Frati F, Incorvaia C, Cadario G, Contiguglia R, Di Gioacchino M, Puccinelli P, Senna GE, Valle C.

Curr Med Res Opin. 2008 Jan;24(1):261-6.

PMID:
18053319
14.

Acute coronary syndromes in Europe: 1-year costs and outcomes.

Taylor MJ, Scuffham PA, McCollam PL, Newby DE.

Curr Med Res Opin. 2007 Mar;23(3):495-503.

PMID:
17355731
15.

Economic aspects of sublingual immunotherapy.

Incorvaia C, Ariano R, Berto P, Ciprandi G, Leo G, Boccardo R, Scurati S, Frati F.

Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4 Suppl):27-30. Review.

PMID:
19944007
16.

The economic costs of severe anaphylaxis in France: an inquiry carried out by the Allergy Vigilance Network.

Flabbee J, Petit N, Jay N, Guénard L, Codreanu F, Mazeyrat R, Kanny G, Moneret-Vautrin DA.

Allergy. 2008 Mar;63(3):360-5. doi: 10.1111/j.1398-9995.2007.01513.x.

17.

Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study.

Hankin CS, Cox L, Lang D, Bronstone A, Fass P, Leatherman B, Wang Z.

Ann Allergy Asthma Immunol. 2010 Jan;104(1):79-85. doi: 10.1016/j.anai.2009.11.010.

PMID:
20143650
18.

Effects of specific immunotherapy on the development of new sensitisations in monosensitised patients.

Tella R, Bartra J, San Miguel M, Olona M, Bosque M, Gaig P, Garcia-Ortega P.

Allergol Immunopathol (Madr). 2003 Jul-Aug;31(4):221-5.

PMID:
12890414
19.

The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort.

Weinmann S, Kamtsiuris P, Henke KD, Wickman M, Jenner A, Wahn U.

Pediatr Allergy Immunol. 2003 Feb;14(1):18-26.

PMID:
12603707
20.

Economic evaluation of sublingual immunotherapy: an analysis of literature.

Ciprandi G, Agostinis F, Amoroso S, Ariano R, Barbato A, Bassi M, Cadario G, Campi P, Cardinale F, Romano C, Incorvaia C, Danneo R, Dal Bo S, Di Gioacchino M, Fiocchi A, Galimberti M, Galli E, Giovannini M, La Grutta S, Lombardi C, Marcucci F, Marseglia GL, Mastrandrea F, Minelli M, Nettis E, Novembre E, Ortolani C, Pajno G, Piras PP, Passalacqua G, Patriarca G, Pucci S, Quercia O, Romano A, Schiavino D, Sforza M, Tosca MA, Tripodi S, Zambito M, Puccinelli P, Frati F.

Eur Ann Allergy Clin Immunol. 2007;39 Spec No:21-6.

PMID:
18924463

Supplemental Content

Support Center